×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EBS – emergent biosolutions inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EBS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/22
06:51 am
ebs
Lyophilization Services for Biopharmaceuticals Industry Research Report 2024-2033: Drivers and Restraints, Competitive Landscape, Future Opportunities and Strategies [Yahoo! Finance]
Low
Report
Lyophilization Services for Biopharmaceuticals Industry Research Report 2024-2033: Drivers and Restraints, Competitive Landscape, Future Opportunities and Strategies [Yahoo! Finance]
11/20
03:11 am
ebs
Emergent BioSolutions Inc. (NYSE: EBS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Emergent BioSolutions Inc. (NYSE: EBS) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/8
10:19 am
ebs
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Low
Report
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/7
02:11 pm
ebs
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 [Yahoo! Finance]
Medium
Report
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 [Yahoo! Finance]
11/7
10:39 am
ebs
Emergent BioSolutions Inc. (NYSE: EBS) had its price target raised by analysts at Benchmark Co. from $8.00 to $12.00. They now have a "buy" rating on the stock.
High
Report
Emergent BioSolutions Inc. (NYSE: EBS) had its price target raised by analysts at Benchmark Co. from $8.00 to $12.00. They now have a "buy" rating on the stock.
11/7
01:28 am
ebs
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/6
05:06 pm
ebs
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa [Yahoo! Finance]
Medium
Report
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa [Yahoo! Finance]
11/6
04:49 pm
ebs
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
Medium
Report
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2024
04:05 pm
EBS
emergent biosolutions inc.
BEAT
Report
18.4%
emergent biosolutions inc.
8/6/2024
05:01 pm
EBS
emergent biosolutions inc.
MISS
Report
-35.0%
emergent biosolutions inc.
3/6/2024
04:31 pm
EBS
emergent biosolutions inc.
MISS
Report
-17.3%
emergent biosolutions inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:03 pm
ebs
Form 3 Emergent BioSolutions For: Nov 18 Filed by: Lowry Simon C
Low
Report
Form 3 Emergent BioSolutions For: Nov 18 Filed by: Lowry Simon C
11/14
04:19 pm
ebs
Form 4 Emergent BioSolutions For: Nov 12 Filed by: DeGolyer Donald W
High
Report
Form 4 Emergent BioSolutions For: Nov 12 Filed by: DeGolyer Donald W
11/13
04:05 pm
ebs
Form 4 Emergent BioSolutions For: Nov 11 Filed by: Hartzel William
Medium
Report
Form 4 Emergent BioSolutions For: Nov 11 Filed by: Hartzel William
11/13
04:05 pm
ebs
Form 4 Emergent BioSolutions For: Nov 11 Filed by: White Marvin L
Medium
Report
Form 4 Emergent BioSolutions For: Nov 11 Filed by: White Marvin L
11/13
04:01 pm
ebs
Form SC 13G Emergent BioSolutions Filed by: OAK HILL ADVISORS LP
High
Report
Form SC 13G Emergent BioSolutions Filed by: OAK HILL ADVISORS LP
11/12
05:16 pm
ebs
Form 144 Emergent BioSolutions Filed by: DeGolyer Donald W
Medium
Report
Form 144 Emergent BioSolutions Filed by: DeGolyer Donald W
11/12
04:26 pm
ebs
Form 3 Emergent BioSolutions For: Oct 29 Filed by: Perl Jessica
Medium
Report
Form 3 Emergent BioSolutions For: Oct 29 Filed by: Perl Jessica
11/12
04:07 pm
ebs
Form S-1 Emergent BioSolutions
Medium
Report
Form S-1 Emergent BioSolutions
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/30
Emergent BioSolutions (EBS) Investor Presentation - Slideshow [Seeking Alpha]
14.7%
9/4 Form 8-K Emergent BioSolutions For: Aug 30 10.7%
3/10 Here's Why Emergent Biosolutions, BioMarin, and Nuvasive Fell on Monday [The Motley Fool] 10.2%
3/4 Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite 9.2%
5/1 Form 8-K/A Emergent BioSolutions For: Apr 30 8.9%
4/23 Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19 8.5%
6/3 Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness 8.2%
4/27 Emergent Biosolutions Inc (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $71.00 price target on the stock. 7.2%
2/27 Form 4 Emergent BioSolutions For: Feb 25 Filed by: Strei Katherine 6.1%
3/11 Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease 5.3%
9/4 Form 8-K Emergent BioSolutions For: Aug 30 10.7%
3/10 Here's Why Emergent Biosolutions, BioMarin, and Nuvasive Fell on Monday [The Motley Fool] 10.2%
3/4 Emergent BioSolutions Selects Axiom Fusion eClinical Suite as Its Global eClinical Suite 9.2%
5/1 Form 8-K/A Emergent BioSolutions For: Apr 30 8.9%
4/23 Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19 8.5%
6/3 Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness 8.2%
4/27 Emergent Biosolutions Inc (NYSE: EBS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $71.00 price target on the stock. 7.2%
2/27 Form 4 Emergent BioSolutions For: Feb 25 Filed by: Strei Katherine 6.1%
3/11 Emergent BioSolutions Initiates Development of Plasma-Derived Product Candidates for the Treatment and Prevention of Coronavirus Disease 5.3%
TOP News Decliners
3/13
Why These Drug Stocks Soared Today [The Motley Fool]
-15.6%
3/6 Form 3/A Emergent BioSolutions For: Mar 05 Filed by: Kirk Sean -10.5%
11/7 Emergent Biosolutions Inc (NYSE: EBS) had its "hold" rating re-affirmed by analysts at Cowen Inc. They now have a $67.00 price target on the stock. -10.0%
3/10 Here's Why Emergent BioSolutions Jumped Higher on Tuesday [The Motley Fool] -9.3%
3/31 Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™ -6.1%
4/20 Form 4 Emergent BioSolutions For: Apr 16 Filed by: El-Hibri Fuad -5.7%
10/21 Emergent BioSolutions to Host 2019 Analyst & Investor Day -5.2%
9/10 Form 4 Emergent BioSolutions For: Sep 09 Filed by: Zoon Kathryn C -4.9%
3/2 Form 4 Emergent BioSolutions For: Feb 27 Filed by: Bailey Sue -4.6%
10/7 Here’s Why Emergent BioSolutions Stock Climbed 19.4% in September [The Motley Fool] -4.2%
3/6 Form 3/A Emergent BioSolutions For: Mar 05 Filed by: Kirk Sean -10.5%
11/7 Emergent Biosolutions Inc (NYSE: EBS) had its "hold" rating re-affirmed by analysts at Cowen Inc. They now have a $67.00 price target on the stock. -10.0%
3/10 Here's Why Emergent BioSolutions Jumped Higher on Tuesday [The Motley Fool] -9.3%
3/31 Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™ -6.1%
4/20 Form 4 Emergent BioSolutions For: Apr 16 Filed by: El-Hibri Fuad -5.7%
10/21 Emergent BioSolutions to Host 2019 Analyst & Investor Day -5.2%
9/10 Form 4 Emergent BioSolutions For: Sep 09 Filed by: Zoon Kathryn C -4.9%
3/2 Form 4 Emergent BioSolutions For: Feb 27 Filed by: Bailey Sue -4.6%
10/7 Here’s Why Emergent BioSolutions Stock Climbed 19.4% in September [The Motley Fool] -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: